NeuroPace, Inc. (NPCE)
Full history for every metric is available with a Kvantra account
No price history available.
Key financial summary
Financials in USD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Total revenue | $m | 41 | 45 | 46 | 65 | 80 | 100 | 99 | 100 |
| Operating profit | $m | -16 | -15 | ||||||
| Net profit | $m | -24 | -36 | -47 | -33 | -27 | -21 | -19 | -19 |
| EPS reported | $ | -0.66 | -0.57 | ||||||
| Operating cashflow per share | $ | -0.34 | -0.33 | ||||||
| Capex per share | $ | 0.01 | 0.01 | ||||||
| FCF per share | $ | -0.35 | -0.34 | ||||||
| Free cash flow | $m | -11 | -12 | ||||||
| Net debt | $m | -0 | 7 | ||||||
| Book value equity | $m | 19 | 12 | ||||||
| Book value per share | $ | 0.58 | 0.35 | ||||||
| Number of shares | m | 32.72 | 34.1 | ||||||
| DPS (TTM paid) | $ | 0.00 | 0.00 |
Financial summary
Financials in USD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Value | |||||||||
| P/E TTM | x | - | - | ||||||
| P/B LTM | x | 26.55 | 42.52 | ||||||
| P/S LTM | x | 5.05 | 5.11 | ||||||
| P/FCF LTM | x | -44.56 | -43.52 | ||||||
| EV/EBITDA LTM | x | -45.97 | -45.12 | ||||||
| EV/Sales LTM | x | 5.54 | 5.68 | ||||||
| Earnings Yield LTM | % | -4.25% | -3.79% | ||||||
| FCF Yield | % | -2.24% | -2.30% | ||||||
| Quality | |||||||||
| ROE | % | -112.79% | -119.68% | ||||||
| ROIC | % | -18.18% | -18.43% | ||||||
| Operating margin | % | -16.34% | -15.26% | ||||||
| Gross margin | % | +77.23% | +79.63% | ||||||
| FCF/Sales | % | -11.34% | -11.75% | ||||||
| Growth and momentum | |||||||||
| EPS Growth YoY | % | - | - | ||||||
| Sales Growth YoY | % | +25.13% | +23.69% | ||||||
| Net Income Growth YoY | % | - | - | ||||||
| FCF Growth | % | - | - | ||||||
| Operating Profit Growth | % | - | - | ||||||
| Dividend and capital structure | |||||||||
| Dividend Yield | % | 0.00% | 0.00% | ||||||
| Dividend Growth | % | - | - | ||||||
| Payout Ratio | % | 0.00% | 0.00% | ||||||
| FCF/Debt | x | -0.16 | -0.17 | ||||||
| Net Debt/EBITDA | x | -4.08 | -4.67 | ||||||
| EBIT/Net interest | x | -2.19 | -2.39 | ||||||
| Net debt/market cap | % | +12.07% | +11.72% | ||||||
| Net debt/Equity | x | -0.00 | 0.62 | ||||||
| Gross debt/equity | x | 3.72 | 5.88 | ||||||
Price target estimates
Based on consensus from external analysts. Not Kvantra's opinion.
Ratings
Based on consensus from external analysts. Not Kvantra's opinion.
ESG
| Metric | 2024 | 2025 | 2026 |
|---|---|---|---|
| ESG-score | |||
| Environmental score | |||
| Social score | |||
| Governance score | |||
| Risk rating |
Company overview
NeuroPace, Inc. operates as a medical device company in the United States. The company develops RNS system, a brain-responsive neuromodulation system that delivers personalized, real-time treatment at the seizure source for treating drug-resistant focal epilepsy. Its RNS System includes RNS neurostimulator, cortical strip and depth leads, and Patient Remote Monitor, as well as other implantable and non-implantable accessories. In addition, the company provides physician tablet which is used for prescribing and managing clinicians for programming implanted devices and managing patient care; and patient data management system, a secure online database that collects data that have been recorded by the RNS System; and nSight Platform, which provide clinicians with personalized patient reports, as well as programming suggestions. It sells its products to hospital facilities for initial RNS System implant procedures and for replacement procedures. NeuroPace, Inc. was incorporated in 1997 and is headquartered in Mountain View, California.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
No price history available.
Consensus from external analysts. Not Kvantra's opinion.
Based on consensus from external analysts. Not Kvantra's opinion.
NeuroPace, Inc. operates as a medical device company in the United States. The company develops RNS system, a brain-responsive neuromodulation system that delivers personalized, real-time treatment at the seizure source for treating drug-resistant focal epilepsy. Its RNS System includes RNS neurostimulator, cortical strip and depth leads, and Patient Remote Monitor, as well as other implantable and non-implantable accessories. In addition, the company provides physician tablet which is used for prescribing and managing clinicians for programming implanted devices and managing patient care; and patient data management system, a secure online database that collects data that have been recorded by the RNS System; and nSight Platform, which provide clinicians with personalized patient reports, as well as programming suggestions. It sells its products to hospital facilities for initial RNS System implant procedures and for replacement procedures. NeuroPace, Inc. was incorporated in 1997 and is headquartered in Mountain View, California.
Unlock all fundamental data
Sign up for FreeUnlock all fundamental data
Sign up for Free